Tumors of the peripheral nerves and plexuses

Current Treatment Options in Neurology

Volumn 8, Issue 4, 2006, Pages 299-308

  Huang, Jason H ^a   Johnson, Victoria E ^b   Zager, Eric L ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; COSMETIC; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; IFOSFAMIDE; MESNA; NEUROFIBROMIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P16; PROTEIN P21; PROTEIN P53; RAS PROTEIN; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; BENIGN TUMOR; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RISK; CARDIOTOXICITY; CHROMOSOME 17; CHROMOSOME 22; CHROMOSOME MUTATION; CLINICAL TRIAL; COMA; CONFUSION; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; DECOMPRESSION SURGERY; DIAGNOSTIC IMAGING; DIETARY INTAKE; DRUG COST; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; ELECTRON THERAPY; FOLLOW UP; GENETIC DISORDER; GENOTYPE PHENOTYPE CORRELATION; HALLUCINATION; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; INFERTILITY; KIDNEY DYSFUNCTION; LIFESTYLE; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NERVE SHEATH TUMOR; NERVE STIMULATION; NEURILEMOMA; NEUROFIBROMATOSIS; NEUROLOGIC DISEASE; NEUROTOXICITY; OCCUPATIONAL THERAPY; PAIN; PERIPHERAL NERVE TUMOR; PHYSIOTHERAPY; PROGNOSIS; REVIEW; SOMNOLENCE; SURVIVAL RATE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR RECURRENCE; WOUND HEALING IMPAIRMENT;

EID: 33745390152     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-006-0020-z     Document Type: Review

References (58)

1. Harkin J, Reed RJ: Tumors of the Peripheral Nervous System. Washington DC: Armed Forces Institute of Pathology; 1969.
2. Kleihues P, Cavenee WK: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Nervous System. Lyon, France: AZRC Press; 2000.
3. Kransdorf M, Murphay MD: Neurogenic tumors. In Imaging of Soft Tissue Tumors. Philadelphia: Saunders; 1997:235-273.
4. Skovronsky DM, Oberholtzer JC: Pathologic classification of peripheral nerve tumors. Neurosurg Clin N Am 2004, 15:157-166.
5. Pilavaki M, Chourmouzi D, Kiziridou A, et al.: Imaging of peripheral nerve sheath tumors with pathologic correlation: pictorial review. Eur J Radiol 2004, 52:229-239.
6. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988, 45:575-578.
7. Huang JH, Zaghloul K, Zager EL: Surgical management of brachial plexus region tumors. Surg Neurol 2004, 61:372-378.
8. Moukarbel RV, Sabri AN: Current management of head and neck schwannomas. Curr Opin Otolaryngol Head Neck Surg 2005, 13:117-122.
9. Ducatman BS, Scheithauer BW Piepgras DG, et al.: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986, 57:2006-2021.
10. Collin C, Godbold J, Hajdu S, Brennan M: Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 1987, 5:601-612.
11. Perrin RG, Guha A: Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am 2004, 15:203-216.
12. Sorensen SA, Mulvihill JJ, Nielsen A: Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 1986, 314:1010-1015.
13. Kourea HP, Bilsky MH, Leung DH, et al.: Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors. Cancer 1998, 82:2191-2203.
14. Ducatman BS, Scheithauer BW: Postirradiation neurofibrosarcoma. Cancer 1983, 51:1028-1033.
15. Foley KM, Woodruff JM, Ellis FT, Posner JB: Radiation-induced malignant and atypical peripheral nerve sheath tumors. Ann Neurol 1980, 7:311-318.
16. Giannini C, Scheithauer BW, Jenkins RB, et al.: Soft-tissue perineurioma. Evidence for an abnormality of chromosome 22, criteria for diagnosis, and review of the literature Am J Surg Pathol 1997, 21:164-173.
17. Woodruff JM: The pathology and treatment of peripheral nerve tumors and tumor-like conditions. CA Cancer J Clin 1993, 43:290-308.
18. Wallace MR, Marchuk DA, Andersen LB, et al.: Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990, 249:181-186.
19. Gutmann DH: Recent insights into neurofibromatosis type 1: clear genetic progress. Arch Neurol 1998, 55:778-780.
20. Seymour-Dempsey K, Andrassy RJ: Neurofibromatosis: implications for the general surgeon. J Am Coll Surg 2002, 195:553-563.
21. Korf BR: Clinical features and pathobiology of neurofibromatosis 1. J Child Neurol 2002, 17:573-577.
22. Zoller M, Rembeck B, Akesson HO, Angervall L: Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Goteborg, Sweden. Acta Derm Venereol 1995, 75:136-140.
23. Brooks DG: The neurofibromatoses: hereditary predisposition to multiple peripheral nerve tumors. Neurosurg Clin N Am 2004, 15:145-155.
24. Evans DG, Sainio M, Baser ME: Neurofibromatosis type 2. J Med Genet 2000, 37:897-904.
25. Lim DJ, Rubenstein AE, Evans DG, et al.: Advances in neurofibromatosis 2 (NF2): a workshop report. J Neurogenet 2000, 14:63-106.
26. Martuza RL, Eldridge R: Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988, 318:684-688.
27. Huang JH, Simon SL, Nagpal S, et al.: Management of patients with schwannomatosis: report of six cases and review of the literature Surg Neurol 2004, 62:353-361.
28. Jacoby LB, Jones D, Davis K, et al.: Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 1997, 61:1293-1302.
29. MacCollin M, Woodfin W, Kronn D, Short MP: Schwannomatosis: a clinical and pathologic study. Neurology 1996, 46:1072-1079.
30. Seppala MT, Sainio MA, Haltia MJ, et al.: Multiple schwannomas: schwannomatosis or neurofibromatosis type 2? J Neurosurg 1998, 89:36-41.
31. Kransdorf ML Jelinek JS, Moser RP Jr, et al.: Soft-tissue masses: diagnosis using MR imaging. AIR Am J Roentgenol 1989, 153:541-547.
32. Sundaram M, McGuire MH, Herbold DR: Magnetic resonance imaging of soft tissue masses: an evaluation of fifty-three histologically proven tumors. Magn Reson Imaging 1988, 6:237-248.
33. Maniker AH: Diagnostic steps, imaging, and electro-physiology. Neurosurg Clin N Am 2004, 15:133-144.
34. Kobayashi H, Kotoura Y, Hosono M, et al.: MRI and scintigraphic features of extraabdominal desmoid tumors. Clin Imaging 1997, 21:35-39.
35. Lucas JD, O'Doherty ML, Wong JC, et al.: Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 1998, 80:441-447.
36. Ferner RE, Lucas JD, O'Doherty ML et al.: Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000, 68:353-357.
37. Howe FA, Filler AG, Bell BA, Griffiths JR: Magnetic resonance neurography. Magn Reson Med 1992, 28:328-338.
38. Gutmann DH, Aylsworth A, Carey JC, et al.: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997, 278:51-57.
39. Ferner RE, Gutmann DH: International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002, 62:1573-1577.
40. Donner TR, Voorhies RM, Kline DG: Neural sheath tumors of major nerves. J Neurosurg 1994, 81:362-373.
41. Artico M: Benign neural sheath tumours of major nerves: characteristics in 119 surgical cases. Acta Neurochir (Wien) 1997, 139:1108-1116.
42. Kline D, Hudson A: Nerve Injuries: Surgical Outcomes of Injuries, Entrapments and Tumors. Philadelphia: WB Saunders; 1995.
43. Baehring JM, Betensky RA, Batchelor TT: Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment Neurology 2003, 61:696-698.
44. Huang JH, Weil RJ, Zager EL: Surgical management of common peripheral nerve tumors. Electronic publication update: Medlink; 2004.
45. Angelov L, Davis A, O'Sullivan B, et al.: Neurogenic sarcomas: experience at the University of Toronto. Neurosurgery 1998, 43:56-64.
46. Tiel R, Kline D: Peripheral nerve tumors: surgical principles, approaches, and techniques. Neurosurg Clin N Am 2004, 15:167-175.
47. Santoro A, Tursz T, Mouridsen H, et al.: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in firstline treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995, 13:1537-1545.
48. Santoro A: Advanced soft tissue sarcoma: how many more trials with anthracydines and ifosfamide? Ann Oncol 1999, 10:151-154.
49. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997, 350:1647-1654.
50. MD Consult http://www.mdconsult.com. Accessed December 14, 2005.
51. Khanfir K, Alzieu L, Terrier P, et al.: Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities? Eur J Cancer 2003, 39:1872-1880.
52. Pollack A, Zagars GK, Goswitz MS, et al.: Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int J Radiat Oncol Biol Phys 1998, 42:563-572.
53. Robinson MH, Keus RB, Shasha D, Harrison LB: Is preoperative radiotherapy superior to postoperative radiotherapy in the treatment of soft tissue sarcoma? Eur J Cancer 1998, 34:1309-1316.
54. Leroy K, Dumas V, Martin-Garcia N, et al.: Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol 2001, 137:908-913.
55. Kourea HP, Cordon-Cardo C, Dudas M, et al.: Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol 1999, 155:1885-1891.
56. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, et al.: Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 1999, 155:1879-1884.
57. Ferner RE, O'Doherty MJ: Neurofibroma and schwannoma. Curr Opin Neurol 2002, 15:679-684.
58. NIH Clinical Research Studies (protocol number. 05-C-0232). A phase 1 trial of peginterferon Alfa-2b (PEG-Intron) for plexiform neurofibromas. http://clinicalstudies.info.nih.gov/detail/a_2005-c-0232.html. Accessed December 14, 2005.